Literature DB >> 17318013

B-RAF mutations are a rare event in pituitary adenomas.

I De Martino1, M Fedele, D Palmieri, R Visone, P Cappabianca, A Wierinckx, J Trouillas, A Fusco.   

Abstract

Pituitary tumors are a relatively common neoplasia whose pathogenesis is still largely unknown. Recent studies have revealed frequent activating mutations of the gene for B-RAF, an effector of Ras protein in the mitogen-activated protein kinase pathway, in several malignancies, including melanoma, thyroid, colorectal and ovarian cancer. However, analyses of B-RAF mutations in pituitary tumors have not been reported so far. Therefore, in the present study we have investigated the presence of the B-RAF mutations, by polymerase chain reaction (PCR) amplification of the hot spot exons 11 and 15, followed by direct sequencing, in 50 human pituitary adenomas, including 25 NFPA and 25 secreting adenomas (10 GH, 5 PRL, 6 LH and/or FSH, 4 GH/PRL). We found only one V600E mutation in a NFPA sample, suggesting that B-RAF mutations are a rare event in pituitary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318013     DOI: 10.1007/BF03347386

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  13 in total

Review 1.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

Review 2.  Oncogene activation in pituitary tumors.

Authors:  R Yu; S Melmed
Journal:  Brain Pathol       Date:  2001-07       Impact factor: 6.508

3.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

Authors:  Monica Fedele; Rosa Visone; Ivana De Martino; Giancarlo Troncone; Dario Palmieri; Sabrina Battista; Andrea Ciarmiello; Pierlorenzo Pallante; Claudio Arra; Rosa Marina Melillo; Kristian Helin; Carlo Maria Croce; Alfredo Fusco
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

4.  Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes.

Authors:  R Buscà; P Abbe; F Mantoux; E Aberdam; C Peyssonnaux; A Eychène; J P Ortonne; R Ballotti
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

5.  Cytogenetic study of pituitary adenomas.

Authors:  D Bettio; N Rizzi; D Giardino; L Persani; F Pecori-Giraldi; M Losa; L Larizza
Journal:  Cancer Genet Cytogenet       Date:  1997-10-15

Review 6.  G-proteins and hormonal signalling in human pituitary tumors: genetic mutations and functional alterations.

Authors:  A Spada; L Vallar; G Faglia
Journal:  Front Neuroendocrinol       Date:  1993-07       Impact factor: 8.606

7.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

8.  Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas.

Authors:  Monica Fedele; Sabrina Battista; Lawrence Kenyon; Gustavo Baldassarre; Vincenzo Fidanza; Andres J P Klein-Szanto; A F Parlow; Rosa Visone; Giovanna M Pierantoni; Eric Outwater; Massimo Santoro; Carlo M Croce; Alfredo Fusco
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

9.  Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance.

Authors:  N Hu; A Gutsmann; D C Herbert; A Bradley; W H Lee; E Y Lee
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  2 in total

1.  Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors.

Authors:  G Masi; E Lavezzo; M Iacobone; G Favia; G Palù; L Barzon
Journal:  J Endocrinol Invest       Date:  2009-05-15       Impact factor: 4.256

2.  GH, IGF-1, and Age Are Important Contributors to Thyroid Abnormalities in Patients with Acromegaly.

Authors:  Xia Wu; Lu Gao; Xiaopeng Guo; Qiang Wang; Zihao Wang; Wei Lian; Wei Liu; Jian Sun; Bing Xing
Journal:  Int J Endocrinol       Date:  2018-01-15       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.